Research Article Open Access
Volume 2 | Issue 1 | DOI: https://doi.org/10.33696/haematology.2.022

Lower 24-Month Relative Survival among Black Patients with Non- Hodgkin’s Lymphoma: An Analysis of the SEER Data 1997-2015

  • 1Northwell Health Cancer Institute & Donald and Barbara Zucker School of Medicine at Hofstra, Lake Success, NY, USA
  • 2Wyckoff Medical Center, New York, NY, USA
+ Affiliations - Affiliations

Corresponding Author

Maria J Nieto, mnieto2@northwell.edu

Received Date: November 25, 2020

Accepted Date: January 25, 2021


Background: Recent progress in the therapies used in patients with Non- Hodgkin’s lymphoma has improved survival. The incidence has been reported to be decreasing in the last few years, accounting for 4% of all cancers. This study analyzed time trends for incidence, mortality, and prevalence of NHL.

Methods: We analyzed the SEER Cancer Database from 1997 to 2015. Join point regression analysis was used to determine ageadjusted incidence rates, 24-month relative survival rate, and to identify racial/ethnic groups with a lower survival.

Results: The trend in incidence of NHL decreased between 2008 and 2011 at an annual percentage change rate of 3.74%. The male predominance among NHL patients between 1997-2015 was 57%. The number of male patients affected with NHL has been similar in the last 20 years. Female predominance with NHL was higher in 1998 at 46 %, and lower in 2010 at 42.85%. The 24-month relative survival rate was higher among white patients as compared to black patients with NHL.

Conclusions: Our analysis demonstrated that the incidence of Non-Hodgkin’s Lymphoma has decreased among minorities; however, the outcomes are inferior in terms of survival. This analysis showed an inferior 24-month relative survival rate among black patients compared with white patients. This analysis demonstrates the need for further research in NHL to determine the biological differences and social factors that influence the lower survival among black patients with NHL.


SEER; non-Hodgkin lymphoma; Lymphoma; Rituximab; CHOP regimen; RCHOP; Diffuse large B cell lymphoma; Racial disparities

Author Information X